Autopsy report · NCT04644185

The Efficacy and Safety of SCTA01 in Hospitalized Patients With Severe COVID-19

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“Preclinical test showed reduced efficacy”

The sponsor’s own words in the registry.

Life of this trial

Registered 4 months before it started.
Ran for about 10 months before it stopped.
102 participants enrolled.
Results were posted on the registry 3 years 8 months after it ended.

Vital statistics

Status: Terminated
Phase: Phase 2, Phase 3
Sponsor: Sinocelltech Ltd.
Sponsor type: Industry
Conditions: Covid19
Interventions: SCTA01; Placebo
Participants: 102
Sites: 7
Countries: Argentina, Brazil, Chile, Colombia, Mexico, Peru, United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.